{"id":10119,"date":"2022-09-10T04:31:59","date_gmt":"2022-09-10T04:31:59","guid":{"rendered":"https:\/\/marylanddailygazette.com\/lipodystrophy-pipeline-sees-expansion-owing-to-key-players-key-therapies-and-research-programmes\/"},"modified":"2022-09-10T04:31:59","modified_gmt":"2022-09-10T04:31:59","slug":"lipodystrophy-pipeline-sees-expansion-owing-to-key-players-key-therapies-and-research-programmes","status":"publish","type":"post","link":"https:\/\/marylanddailygazette.com\/lipodystrophy-pipeline-sees-expansion-owing-to-key-players-key-therapies-and-research-programmes\/","title":{"rendered":"Lipodystrophy Pipeline Sees Expansion Owing to Key Players, Key Therapies and Research &amp; Programmes"},"content":{"rendered":"<p><a href=\"https:\/\/www.digitaljournal.com\/pr\/lipodystrophy-pipeline-sees-expansion-owing-to-key-players-key-therapies-and-research-programmes\">Lipodystrophy Pipeline Sees Expansion Owing to Key Players, Key Therapies and Research &#038; Programmes<\/a><\/p>\n<p><div><a href=\"https:\/\/marylanddailygazette.com\/wp-content\/uploads\/2022\/09\/qde3pb.png\" target=\"_blank\" rel=\"nofollow noopener\"><img decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Lipodystrophy Pipeline Sees Expansion Owing to Key Players, Key Therapies and Research &amp; Programmes\" src=\"https:\/\/marylanddailygazette.com\/wp-content\/uploads\/2022\/09\/qde3pb.png\" alt=\"Lipodystrophy Pipeline Sees Expansion Owing to Key Players, Key Therapies and Research &amp; Programmes\" width=\"225\"><\/a><\/div>\n<p><em>\u201c<strong>DelveInsight\u2019s, \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/lipodystrophy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">Lipodystrophy Pipeline<\/a> Insight, 2022,\u201d report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Lipodystrophy pipeline landscape<\/strong>\u201d<\/em><\/p>\n<p>Lipodystrophy Pipeline Insight, 2022\u2033 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lipodystrophy pipeline landscape is provided which includes the disease overview and Lipodystrophy treatment guidelines. The assessment part of the report embraces, in depth Lipodystrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lipodystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.<\/p>\n<p><strong>Key takeaways from the Lipodystrophy Pipeline Report<\/strong><\/p>\n<ul>\n<li>Lipodystrophy Pipeline report offers a comprehensive analysis of 10+key players and 10+key therapies.<\/li>\n<li>Lipodystrophy Emerging Therapies included such <strong><em>as REGN4461 (Regeneron Pharmaceuticals)<\/em><\/strong> and several others<\/li>\n<li>Lipodystrophy Pipeline Companies included such as <strong><em>Regeneron Pharmaceuticals, Galmed Pharmaceuticals, CombiGene, Cell Praxis, Zydus Cadila, Carmot Therapeutics, Lipigon Pharmaceuticals,<\/em><\/strong> and several others.<\/li>\n<\/ul>\n<p>Get more information on the <strong>Lipodystrophy Clinical Trials?- <a href=\"https:\/\/www.delveinsight.com\/sample-request\/lipodystrophy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/sample-request\/lipodystrophy-pipeline-insight <\/a><\/strong><\/p>\n<p><strong>Lipodystrophy Overview<\/strong><\/p>\n<p>Lipodystrophy refers to medical problem where there is an abnormal distribution of fat in the body. The disease may be inherited genetically, (for example, familial partial lipodystrophy or FPLD), or acquired. If inherited it may be present at birth (congenital). There are five types of lipodystrophy: Congenital generalized lipodystrophy, acquired generalized lipodystrophy, Acquired partial lipodystrophy, High active antiretroviral therapy-induced lipodystrophy, and Localized lipodystrophy. The specific symptoms present, severity, and prognosis can vary greatly depending upon the specific type of lipodystrophy and the presence and extent of associated symptoms. To make the medical diagnosis of lipodystrophy the doctor first examine the abnormal appearance caused by changes in fat loss or gain, and then he or she generally look for the characteristic clinical symptoms and signs.<\/p>\n<p><strong>Lipodystrophy Pipeline Report<\/strong><\/p>\n<p>The <strong>Lipodystrophy <\/strong>pipeline report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The <strong>Lipodystrophy <\/strong>pipeline report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers &amp; acquisitions (M&amp;A), funding, designations, and other product-related details.<\/p>\n<p><strong>Lipodystrophy Pipeline Phases<\/strong><\/p>\n<p>DelveInsight\u2019s Report covers around 10+ products under different phases of clinical development like<\/p>\n<ul>\n<li>Late-stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p>The <strong>Lipodystrophy <\/strong>pipeline report proffers a rich coverage of the therapeutics by development stage, product type, and route of administration, molecule type, and MOA type for <strong>Lipodystrophy <\/strong>across the complete product development cycle, including all clinical and non-clinical stages.<\/p>\n<p><a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/report-store\/lipodystrophy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Lipodystrophy Emerging Drugs<\/strong><\/a><\/p>\n<p><strong>REGN4461: Regeneron Pharmaceuticals<\/strong><\/p>\n<p>REGN4461 is a leptin receptor (LEPR) agonist for lipodystrophy and obesity which is being developed by Regeneron Pharmaceuticals. It is currently in the Phase II stage of development. It is administered intravenously or subcutaneously.<\/p>\n<p><strong>Lipodystrophy<\/strong> <strong>Pipeline Analysis<\/strong><\/p>\n<p>The report provides insights into:-<\/p>\n<ul>\n<li>The report provides detailed insights about companies that are developing therapies in the <strong>Lipodystrophy <\/strong>Market.<\/li>\n<li>It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for <strong>Lipodystrophy <\/strong>treatment.<\/li>\n<li><strong>Lipodystrophy <\/strong>key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li><strong>Lipodystrophy <\/strong>Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the <strong>Lipodystrophy <\/strong>market.<\/li>\n<\/ul>\n<p><strong>Lipodystrophy Pipeline Therapeutic Analysis<\/strong><\/p>\n<p>There are approx. 10+ key companies which are developing therapies for Lipodystrophy. The companies which have their Lipodystrophy drug candidates in the most advanced stage, i.e. Phase II include, Regeneron Pharmaceuticals, and others.<\/p>\n<p><strong>Scope of the<\/strong> <strong>Lipodystrophy Pipeline Report<\/strong><\/p>\n<ul>\n<li>Coverage- Global<\/li>\n<li>Lipodystrophy Pipeline Companies- <strong><em>Regeneron Pharmaceuticals, Galmed Pharmaceuticals, CombiGene, Cell Praxis, Zydus Cadila, Carmot Therapeutics, Lipigon Pharmaceuticals<\/em><\/strong>, and several others.<\/li>\n<li>Lipodystrophy Emerging Therapies- <strong><em>REGN4461 (Regeneron Pharmaceuticals<\/em><\/strong><em>), and several others<\/em><\/li>\n<li>Product Profiles<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Impact of Drugs<\/li>\n<\/ul>\n<p><strong>How therapies are transforming the<\/strong> <strong>Lipodystrophy Pipeline Landscape- <a href=\"https:\/\/www.delveinsight.com\/sample-request\/lipodystrophy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/sample-request\/lipodystrophy-pipeline-insight <\/a><\/strong><\/p>\n<p><strong>Table of Content<\/strong><\/p>\n<ol start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Lipodystrophy: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Drug Name: Company Name<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Preclinical stage products<\/li>\n<li>CGT2: CombiGene<\/li>\n<li>Inactive Products<\/li>\n<li>Lipodystrophy Key Companies<\/li>\n<li>Lipodystrophy Key Products<\/li>\n<li>Lipodystrophy- Unmet Needs<\/li>\n<li>Lipodystrophy- Market Drivers and Barriers<\/li>\n<li>Lipodystrophy- Future Perspectives and Conclusion<\/li>\n<li>Lipodystrophy Analyst Views<\/li>\n<li>Lipodystrophy Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p><strong>Download the report to learn more about the Lipodystrophy Pipeline Companies-<a href=\"https:\/\/www.delveinsight.com\/sample-request\/lipodystrophy-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" rel=\"nofollow\"> https:\/\/www.delveinsight.com\/sample-request\/lipodystrophy-pipeline-insight<\/a><\/strong><\/p>\n<p><strong>About Us<\/strong><\/p>\n<p>DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &amp; Acquisitions.<\/p>\n<p><span>Media Contact<\/span><br \/><strong>Company Name:<\/strong> DelveInsight Business Research LLP<br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"http:\/\/www.universalpressrelease.com\/?pr=lipodystrophy-pipeline-sees-expansion-owing-to-key-players-key-therapies-and-research-programmes&amp;type=pra\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=lipodystrophy-pipeline-sees-expansion-owing-to-key-players-key-therapies-and-research-programmes\" alt width=\"1px\" height=\"1px\"><\/p>\n<p>Published Fri, 09 Sep 2022 21:00:14 -0500<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lipodystrophy Pipeline Sees Expansion Owing to Key Players, Key Therapies and Research &#038; Programmes \u201cDelveInsight\u2019s, \u201cLipodystrophy Pipeline Insight, 2022,\u201d report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Lipodystrophy pipeline landscape\u201d Lipodystrophy Pipeline Insight, 2022\u2033 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":10118,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts\/10119"}],"collection":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/comments?post=10119"}],"version-history":[{"count":0,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/posts\/10119\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/media\/10118"}],"wp:attachment":[{"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/media?parent=10119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/categories?post=10119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marylanddailygazette.com\/wp-json\/wp\/v2\/tags?post=10119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}